Dr. Charles Lynde
Dr. Charles Lynde is an Associate Professor in the Department of Medicine at the University of Toronto and holds a clinical teaching position at the University Health Network. He is the Medical Director of Lynde Institute for Dermatology and Lynderm Research. The Lynde Institute for Dermatology is a full service, interdisciplinary dermatology clinic. After receiving his B.Sc. and MD, degrees at the University of Toronto, Dr. Lynde studied Dermatology at the University of British Columbia and the University of Toronto, receiving his Board Certification (Canada and USA) in 1983.
Lynderm Research is under the guidance of Dr. Lynde as principal investigator for more than 30 years and over 300 clinical trials and is actively involved in the management of psoriasis, rosacea, onychomycosis, acne and atopic dermatitis among other dermatological conditions. Dr. Lynde has authored over 200 peer-reviewed articles.
Dr. Lynde has served in various roles for the CDA and AAD, including President of the Canadian Dermatology Association. He is the Editor of the CDA eBulletin and sits on the editorial boards of several journals and provides extensive consulting as well as being on the advisory boards of many pharmaceutical companies. Dr. Lynde is a frequent guest speaker both nationally and internationally at various dermatological conferences. Recognizing the need for external education he is committed to the training of new and current healthcare professionals in his community and residents through the university program.
Friday APR 8
Beyond the Skin: The Feasibility and Value of Systematic Screening for Psoriatic Arthritis
Dermatologists are the gatekeeper to identifying patients with early signs of PsA. However, many dermatologists do not routinely consider screening for possible signs and symptoms of psoriatic arthritis – a common psoriasis comorbidity that causes irreversible joint damage and aggravates co-morbidities.
The data from Phase 1 of the PsA Screening Project will be presented. In an initial assessment survey of 52 Canadian dermatologists, only 17% will screen their moderate-to-severe psoriasis patients for psoriatic arthritis at every follow-up visit. When screening for PsA, only 9% of respondents rely on a validated screening questionnaire. When PsA is suspected, over 50% of dermatologists will refer to a rheumatologist reflecting a need for greater comfort in managing PsA patients in dermatology practice and when appropriate, initiating a referral to rheumatologist. The PsA Screening Project had dermatologists from across the country screen patients using 3 different tools, to establish which tool type was preferred, and what barriers exist that prevent them from adequately screening.
Session Learning Objectives:
- Recognize the impact of frequent screening for PsA on early detection
- Demonstrate the value of using a standardized screening tool for PsA in dermatology practice
- Consider best practices for implementation of systematic screening to improve patient outcomes
Saturday APR 9